Lampert F, Willems W R, Bertram U, Berthold F
Blut. 1987 Aug;55(2):115-20. doi: 10.1007/BF00631782.
In the years 1980-1985 72 children with acute lymphoblastic leukemia were diagnosed and treated by intensive combination chemotherapy (BFM protocols 79, 81, 83). Of these children 33 acquired a Hepatitis B-virus-carrier state with 1983 as the peak year of incidence. Both groups of patients, the infected and the uninfected ones, were comparable as to prognostic factors. All except 8 patients are off chemotherapy after a total duration of treatment of 1 1/2 or 2 years. Probability for event-free survival (life table analysis, maximum observation time 82 months, minimum 12 months) is equal (0.77 vs. 0.75) in both groups. With 3 exceptions, all HBV-infected patients still carry the HBs-antigen in the serum; 22 of the 30 living patients in the infected group developed anti-HBc.
1980年至1985年期间，72名急性淋巴细胞白血病患儿接受了强化联合化疗（BFM方案79、81、83）进行诊断和治疗。其中33名儿童成为乙肝病毒携带者，1983年为发病高峰年。感染组和未感染组两组患者在预后因素方面具有可比性。除8名患者外，所有患者在总治疗时长1.5年或2年后停止化疗。两组的无事件生存率（生命表分析，最长观察时间82个月，最短12个月）相等（0.77对0.75）。除3例例外，所有HBV感染患者血清中仍携带乙肝表面抗原；感染组30名存活患者中有22名产生了抗-HBc。
